Eyenovia Inc (NASDAQ:EYEN) Major Shareholder Purchases $21,775.00 in Stock

Share on StockTwits

Eyenovia Inc (NASDAQ:EYEN) major shareholder Stuart M. Grant purchased 6,700 shares of the stock in a transaction dated Monday, October 14th. The stock was acquired at an average price of $3.25 per share, for a total transaction of $21,775.00. Following the completion of the transaction, the insider now directly owns 2,226,183 shares of the company’s stock, valued at $7,235,094.75. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of NASDAQ EYEN opened at $2.83 on Monday. Eyenovia Inc has a 1 year low of $2.40 and a 1 year high of $6.98. The firm’s 50 day moving average price is $3.22 and its 200 day moving average price is $3.97. The firm has a market cap of $46.04 million, a P/E ratio of -1.55 and a beta of 1.03.

Eyenovia (NASDAQ:EYEN) last announced its earnings results on Wednesday, November 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.05. Analysts anticipate that Eyenovia Inc will post -1.51 EPS for the current fiscal year.

A hedge fund recently raised its stake in Eyenovia stock. Uniplan Investment Counsel Inc. increased its position in shares of Eyenovia Inc (NASDAQ:EYEN) by 22.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 544,896 shares of the company’s stock after acquiring an additional 99,896 shares during the quarter. Uniplan Investment Counsel Inc. owned approximately 3.31% of Eyenovia worth $2,343,000 as of its most recent filing with the SEC. 8.80% of the stock is currently owned by institutional investors.

Several research firms have recently commented on EYEN. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Eyenovia in a research report on Friday. ValuEngine lowered shares of Eyenovia from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Zacks Investment Research upgraded shares of Eyenovia from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research report on Friday, August 16th.

About Eyenovia

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Read More: The four types of profit margin

Insider Buying and Selling by Quarter for Eyenovia (NASDAQ:EYEN)

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.